Physician profile
John Walsh
NPI 1316427560
$1,444.77
in general payments reported to CMS, 2019-2025
25 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2022: $622 · 2023: $13.61 · 2024: $164 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $398.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $645.56 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $169.43 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $92.08 | 2024 | Advantagerib |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.82 | 2025 | Relistor |
| Orexo US, INC. | $51.35 | 2025 | Zubsolv |
| Amgen INC. | $33.13 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $30.84 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $29.41 | 2025 | Belbuca |
| Baxter Healthcare | $28.38 | 2022 | |
| Merck Sharp & Dohme LLC | $27.59 | 2021 | |
| Lilly USA, LLC | $27.23 | 2024 | Zepbound |
| Cerus Corporation | $24.00 | 2024 | Intercept Blood System For Platelets |
| Amarin Pharma, INC. | $23.53 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.61 | 2025 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $22.33 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.38 | 2025 | Symbravo |
| Haemonetics Corporation | $21.12 | 2024 | Teg6s Hemostasis System |
| Novo Nordisk INC | $20.76 | 2022 | |
| Indivior INC. | $16.15 | 2025 | Sublocade |
| Novartis Pharmaceuticals Corporation | $14.27 | 2022 | |
| Davol INC. | $13.61 | 2023 | Ventralight St |
| Bayer Healthcare Pharmaceuticals INC. | $13.57 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.38 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.24 | 2021 | |
| Medtronic, INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.